PTEN and breast cancer: As Pipp−/−;Pten+/− mice developed end-stage lymphadenopathy by ~7 months of age, examining mammary tumor growth was not feasible and ideally in future studies we will examine the effects of Pipp deletion in mammary-specific Pten−/− mice.